A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma

Published:2022-12 Issue: Volume:135 Page:106219
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Dennis Michael J.,Sacco Assuntina G.,Qi Yuchen,Bykowski Julie,Pittman Emily,Chen Ruifeng,Messer Karen,Cohen Ezra E.W.,Gold Kathryn A.

Funder

Merck

University of California, San Diego

Pfizer

Pfizer Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference27 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021

2. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

3. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522;Ang;J Clin Oncol,2014

4. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial;Gillison;The Lancet,2019

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;The Lancet,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer;Pharmaceutics;2024-09-11

2. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

3. The role of targeting CDK4/6 in cancer immunotherapy;Holistic Integrative Oncology;2024-06-27

4. The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML;Molecular Cancer Therapeutics;2024-03-20

5. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3